Salt Lake City Case-Based Hematology Conference: Translating Guidelines and Innovation into Clinical Practice
The Salt Lake City Case-Based Hematology Conference: Translating Guidelines and Innovation into Clinical Practice is a CME-accredited, in-person hematology conference featuring leading hematology experts. Expert faculty will place recent updates into clinical context and discuss how the results may change the current standards of care for patients with malignant hematologic disorders. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.
This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients.
Target Audience
- Hematologists/Oncologists
- Oncology Nurse Practitioners
- Oncology Pharmacists
- Oncology Physician Assistants
- Oncology Fellows/Residents
- Oncology Nurses
Organizing Committee
Program Director:
Binay Shah, MD, MHA - Binaytara
Conference Chair:
Srinivas Tantravahi, MBBS, MRCP - Huntsman Cancer Institute - University of Utah
Learning Objectives
Upon successful completion of this educational activity on precision oncology, participants will be able to:
- Review recent updates & discuss their applications in clinical settings.
- Choose new therapeutic options for treating malignant hematologic disorders, understanding appropriate indications and contraindications to these therapeutic approaches.
- Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology.
- Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and hematology patients.
- Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.
Saturday, August 16, 2025
All times are listed in Mountain Daylight Time (MDT)
08:00 AM – 09:00 AM Registration, Breakfast, & Exhibits
09:00 AM – 09:05 AM Welcome
09:05 AM – 09:20 AM Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA
09:20 AM – 10:20 AM Session 1 - Leukemia
Session Chair:
09:20 AM – 09:40 AM Menin Matters: Menin Inhibitors of Acute Leukemia
09:40 AM – 10:00 AM Minimizing toxicity, Maximizing response: Obe-cel’s Differentiated Approach in R/R B-ALL
10:00 AM – 10:20 AM STAMPing Out CML Early: Asciminib in the Newly Diagnosed Setting
10:20 AM – 10:30 AM Break & Exhibits
10:30 AM – 11:30 AM Session 2 - Case Based Discussion: Leukemia
Session Chair:
10:30 AM – 10:40 AM Case presentation: Acute Myeloid Leukemia
10:40 AM – 11:00 AM Panel Discussion: Targeting the Menin-MLL Axis: What’s Next for AML Therapy?
11:00 AM – 11:10 AM Case presentation: B-Acute Lymphoblastic leukemia
11:10 AM – 11:30 AM Panel Discussion: Redefining B-ALL Therapy: The Expanding Role of CD19 Directed Therapy
11:30 AM – 12:30 PM Session 3 - Lymphoma
Session Chair:
11:30 AM – 11:50 AM Beyond R-CHOP: Redefining Frontline Therapy in DLBCL
11:50 AM – 12:10 PM Time-Limited vs Continuous Therapy: Where Do They Fit in the CLL Treatment Sequence
12:10 PM – 12:30 PM Hodgkin Lymphoma in the Modern Era: Moving Past the ABVD Standard
12:30 PM – 01:30 PM Lunch & Exhibits
01:30 PM – 02:30 PM Session 4 - Multiple Myeloma
Session Chair:
01:30 PM – 01:50 PM Quadruplets, Transplant, MRD — Is There a Clear Path in Newly Diagnosed Multiple Myeloma?
01:50 PM – 02:10 PM From CAR-T to Bispecifics and Back: Navigating Therapeutic Sequencing in R/R Myeloma
02:10 PM – 02:30 PM Innovating PNH Management: The Promise of Oral Proximal Complement Inhibitors
02:30 PM – 03:30 PM Session 5 - Case Based Discussion
Session Chair:
02:30 PM – 02:40 PM Case presentation: Multiple myeloma
02:40 PM – 03:00 PM Panel Discussion: Harnessing MRD in Myeloma: Timing, Techniques, and Clinical Impact
03:00 PM – 03:10 PM Case presentation: Lymphoma (focused on CD19-directed therapy)
03:10 PM – 03:30 PM Panel Discussion: CD19-Directed Therapies: A New Era in the Treatment of Indolent and Aggressive Lymphomas
03:30 PM Adjourn
Additional details coming soon.
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
FACULTY INFORMATION COMING SOON
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.